{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-025867","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.137979+00:00","generated_at":"2026-06-05T04:27:58.683116+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orthofix Q4 net sales $200.4M (+7% pro forma constant currency); FY24 guidance implies 5-7% growth","bullets":["Q4 net sales $200.4M; Bone Growth Therapies up 15% YoY; U.S. spine fixation up 13.5%.","Q4 net loss $(22.2)M ($(0.59)/share); Non-GAAP adjusted EBITDA $19.6M (9.8% of sales), up 96% YoY pro forma.","Full-year 2023 net sales $746.6M; net loss $(151.4)M; adjusted EBITDA $46.3M (6.2% of sales), up 69%.","FY24 guidance: net sales $785M-$795M (5-7% constant currency growth); adjusted EBITDA $62M-$67M; exit Q4 FCF positive.","Achieved $32M in annualized merger-related synergies; cash $37.8M, $100M drawn on $150M credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-025867","json":"https://secwatch.observer/filing/0000950170-24-025867.json","markdown":"https://secwatch.observer/filing/0000950170-24-025867.md","text":"https://secwatch.observer/filing/0000950170-24-025867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/0000950170-24-025867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/ofix-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:27:58.683116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9e39a66a8c3cbd4935e5e0468404e5a36c34cf7","claim":"Orthofix Medical Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $200.4 million, net income $(22.2) million, EPS $(0.59).","evidence_excerpt":"Fourth quarter net sales were $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Net loss was $(22.2) million and earnings per share (\"EPS\") was $(0.59) on a reported basis, representing an improvement of 19% when compared to pro forma results for the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024025867/0000950170-24-025867-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$200.4 million"},{"label":"Net income","value":"$(22.2) million"},{"label":"EPS","value":"$(0.59)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}